A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future TmodTM CAR T Therapy Portfolio News / By Karina Tin January 18, 2022 A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future TmodTM CAR T Therapy Read More »
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference Portfolio News / By Karina Tin January 11, 2022 Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference Read More »
NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs Portfolio News / By Karina Tin January 10, 2022 NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs Read More »
Tenaya Therapeutics Provides 2022 Business Updates Portfolio News / By Karina Tin January 10, 2022 Tenaya Therapeutics Provides 2022 Business Updates Read More »
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline Portfolio News / By Karina Tin January 10, 2022 Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline Read More »
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Portfolio News / By Karina Tin January 10, 2022 ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Read More »
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts Portfolio News / By Karina Tin January 10, 2022 Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts Read More »
Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team Portfolio News / By Karina Tin January 6, 2022 Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team Read More »
Escient Pharmaceuticals Appoints Joshua Grass, MBA As CEO Portfolio News / By Karina Tin January 5, 2022 Escient Pharmaceuticals Appoints Joshua Grass, MBA As CEO Read More »
Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Portfolio News / By Karina Tin December 23, 2021 Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System Read More »
